-
-
-
-
-
-
-
Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)
-
-
-
-
-
-
-
Gilead exercises option for Assembly Bio's herpes treatment programs
-
-
-
-
-
-
-
Gilead Sciences Announces Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Gilead posts flat second quarter profit, ups full-year outlook on strong HIV sales
-
-
-
-
-
-
-
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
-
-
-
-
-
-
-
Gilead Sciences Announces First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Gilead Sciences Announces Fourth Quarter and Full Year 2024 Financial Results
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

